(Q44551861)

English

Improvement of serum oxidation by pravastatin might be one of the mechanisms by which endothelial function in dilated coronary artery segments is ameliorated

scientific article published in August 2003

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Improvement of serum oxidation by pravastatin might be one of the mechanisms by which endothelial function in dilated coronary artery segments is ameliorated (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

0 references

Aeilko H Zwinderman

5

object named as

Aeilko H Zwinderman

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Martin Jan Schalij

2

object named as

Martin J Schalij

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

author name string

Han J G H Mulder

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Arnoud van der Laarse

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Leny Hollaar

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Albert V G Bruschke

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

publication date

1 August 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Atherosclerosis

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

169

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

309-315

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Endothelial dysfunction: does it matter? Is it reversible?

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Whole plasma oxidation assay as a measure of lipoprotein oxidizability

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Continuous monitoring of in vitro oxidation of human low density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Pathogenesis of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Copper-induced lipid oxidation in unfractionated plasma: the lag preceding oxidation as a measure of oxidation-resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Pravastatin and endothelium dependent vasomotion after coronary angioplasty: the PREFACE trial

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution. Results from the Framingham Offspring Study

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

How to characterize a biological antioxidant

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Effect of Antioxidants on Oxidative Modification of LDL

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Lipid oxidation in unfractionated serum and plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

How different constituents of human plasma and low density lipoprotein determine plasma oxidizability by copper

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Systematic review on the risk and benefit of different cholesterol-lowering interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Enhanced oxidizability of ubiquinol and alpha-tocopherol during lovastatin treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

The effect of lovastatin treatment on low-density lipoprotein hydrated density distribution and composition in patients with intermittent claudication and primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Possible role of high susceptibility of high-density lipoprotein to lipid peroxidative modification and oxidized high-density lipoprotein in genesis of coronary artery spasm

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Lysophosphatidylcholine increases vascular superoxide anion production via protein kinase C activation.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Endothelial dysfunction in Type 1 diabetes mellitus: relationship with LDL oxidation and the effects of vitamin E

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900197-7

7 January 2021

Identifiers

10.1016/S0021-9150(03)00197-7

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44551861&oldid=2190166157"